Gilead Viread patents shot down as company posts strong fourth quarter results

Share this article:
It's been a roller coaster week for Gilead Sciences as the company posted strong fourth quarter 2007 results Tuesday and had four patents for its combination AIDS drug Viread (tenofovir disoproxil fumarate) rejected Wednesday.

Viread is also sold as part of Gilead's two-drug combination AIDS pill Truvada and as a component of the newer Atripla, which combines Truvada with Bristol-Myers Squibb Sustiva into a single pill.
“The process may take some time, but we don't believe the exclusivity of our product is in jeopardy,” Gilead spokeswoman Amy Flood said in a published report.

Meanwhile, Friedman Billings Ramsey & Co. analyst Jim Reddoch upgraded Gilead stock from market perform to outperform following after the company posted strong fourth quarter results Tuesday for its Truvada franchise, which has continued to grow well at a time when many thought it would be contracting.

Truvada had a very strong fourth quarter, beating the Street by 8% and growing 10%
“It sounds like many patients are actually receiving Atripla first line, and then going on Truvada with a protease inhibitor in second line, which means Atripla is not necessarily a cannibalizing factor,” Reddoch wrote. “This is something we had not counted on. After 44% growth in 2007, Gilead's HIV franchise should be good for 28% growth in 2008, especially if the market continues to grow 9%. An expansion of Medicaid (as seems to be on the Democrats' agenda) could provide upside to Gilead's 2009 sales in the US”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...